Key Considerations Before Investing in ELAN

By Susan Ramirez • Tuesday, September 23 15:33 • Permanent Link

Mid-cap Health Care company Elanco Animal Health has moved -2.5% so far today on a volume of 2,908,257, compared to its average of 7,102,522. In contrast, the S&P 500 index moved -1.0%.

Elanco Animal Health trades 0.05% away from its average analyst target price of $18.55 per share. The 11 analysts following the stock have set target prices ranging from $16.0 to $21.0, and on average have given Elanco Animal Health a rating of buy.

Anyone interested in buying ELAN should be aware of the facts below:

Elanco Animal Health's current price is 35.5% above its Graham number of $13.69, which implies that at its current valuation it does not offer a margin of safety
Elanco Animal Health has moved 37.1% over the last year, and the S&P 500 logged a change of 16.8%
Based on its trailing earnings per share of 0.88, Elanco Animal Health has a trailing 12 month Price to Earnings (P/E) ratio of 21.1 while the S&P 500 average is 29.3
ELAN has a forward P/E ratio of 19.7 based on its forward 12 month price to earnings (EPS) of $0.94 per share
Its Price to Book (P/B) ratio is 1.36 compared to its sector average of 3.19
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Based in Greenfield, the company has 9,000 full time employees and a market cap of $9.22 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.